Mary Vore

Revised 1/13/2013

CURRICULUM VITAEMARY VORE

Date of Birth: June 27, 1947

Place of Birth: Guatemala, Central America

Marital Status: Married (Edgar T. Iwamoto, Ph.D.) Children: Kenneth Edgar; Daniel Vore

Home Address: 1229 Summit Drive Lexington, Kentucky 40502 (859) 266-4556 (home) (859) 257-3760 (office)

Citizenship: U.S.A.

Education: 1968; B.A. (cum laude), Asbury College, Wilmore, KY Major: Biology-Pre Med.

1972; Ph.D. Pharmacology, Vanderbilt School ofMedicine, Nashville, Tennessee 37232

Research and Professional Experience

2010 – 2011 Associate Dean for Faculty Advancement

1998 – 2002 Director of Graduate Studies, Graduate Center for Toxicology

1994 - Present: Director, Graduate Center for Toxicology306 HSRB Chandler Medical CenterLexington, Kentucky 40536-0305

July 1990 - March 1991: Acting Chair, Department of Pharmacology University of Kentucky

1986 - 1998 Professor, Department of Pharmacology University of Kentucky College of Medicine

1983 - 1990: Vice-Chairman, Department of Pharmacology University of Kentucky College of Medicine

1981 - 1986: Associate Professor, Department of Pharmacology University of Kentucky College of Medicine

1979 - Present: Graduate Faculty, Graduate Center for ToxicologyUniversity of Kentucky

1978 - 1981: Assistant Professor, Department of Pharmacology University of Kentucky

1

Mary Vore

1974 - 1978: Assistant Professor of Toxicology & PharmacologyDepartment of PharmacologyUniversity of California San Francisco

1972 - 1974: Postdoctoral Fellow Department of Biochemistry and Drug MetabolismHoffmann-LaRoche, Inc. with Dr. Antony YH LuNutley, New Jersey 07110

1968 - 1972: Predoctoral Student Department of PharmacologyVanderbilt School of MedicineVanderbilt UniversityNashville, Tennessee 37232

Memberships: American Society for Pharmacology and Experimental TherapeuticsSociety of ToxicologyAmerican Association for the Study of Liver DiseaseAmerican Association for Cancer Research

Awards:Dean’s Distinguished Lecture – 2009Sturgill Award - Graduate Education, 1998Research Champion, College of Medicine, 1997College of Medicine Faculty Research Award, 1993

2

Mary Vore

Publications - Refereed Journals

1. Vore M, B Sweetman and MT Bush: The metabolism 1-n-butyl-5,5-diethyl-barbituric acid (N-n-butylbarbital) in the rat. J Pharmacol Exp Ther 190:384-394, 1974.

2. Vore M, JG Hamilton and AYH Lu: Organic solvent extraction of liver microsomal lipid. 1. The requirement of lipid for 3,4-benzypyrene hydroxylase. Biochem Biophys Res Commun 56:1038-1044, 1974.

3. Lu, AYH, SG West, M Vore, D Ryan and WJ Levin: Liver microsomal electron transport system. 1. Role of cytochrome b5 in hydroxylation by reconstituted cytochrome P-450 containing system. J Biol Chem 249:6701-6709, 1974.

4. West SB, W Levin, D Ryan, M. Vore and AYH Lu: Liver microsomal electron transport systems. The involvement of cytochrome b5 in the NADH-dependent hydroxylation of 3,4-benzypyrene by a reconstituted cytochrome P-448 containing system. Biochem Biophys Res Commun 58:516-522, 1974.

5. Vore M, AYH Lu, R Kuntzman and AH Conney: Organic solvent extraction of liver microsomal lipid. II. Effect on the metabolism of substrates and binding spectra of cytochrome P-450. Mol Pharmacol 10:863-974, 1974.

6. Goodman DR, PJ Hakkinen, JH Nemenzo and M Vore: Mutagenic evaluation of nitrofuran derivatives in Salmonella typhimurium, by the micronucleus test, and by in vitro cytogenetics. Mutation Res 48:295-306, 1977.

7. Aufrere MB, B Hoener and ME Vore: A high-performance liquid chromatographic assay for nitrofurantoin in plasma and urine. Clin Chem 23:2207-2212, 1977.

8. Marietta, MP, M Vore, WL Way and AJ Trevor: Characterization of liver microsomal enzyme induction by ketamine. Biochem Pharmacol 26:2451-2453, 1977.

9. Vore M, J Bauer and V Pascucci: The effect of pregnancy on the metabolism of 14C-phenytoin in the isolated perfused rat liver. J Pharmacol Exp Ther 206:439-447, 1978.

10. Aufrere MB, B Hoener and M Vore: Reductive metabolism of nitrofurantoin in the rat. Drug Met Dispos 6:403-411, 1978.

11. Vore M, E Soliven and M Blunden: The effect of pregnancy on the biliary excretion of 14C-phenytoin in the rat. J Pharmacol Exp Ther 208:257-262, 1979.

12. Vore M and E Soliven: Organic solvent extraction of liver microsomal lipid. II. Effect on the kinetic parameters of benzo(a)pyrene hydroxylase and benzphetamine-N-demethylase activities. Biochem Pharmacol 28:3659-3665, 1979.

13. Vore M and E Soliven: Hepatic estrone and estradiol glucuronyl- transferase activity in pregnancy: Induction by pretreatment with 3-methylcholanthrene and phenobarbital. Drug Met Dispos 7:247-251, 1979.

14. Vore M and MT Bush: The metabolism of l-n-butyl-5,5-diethyl-barbituric acid (N-n-butylbarbital) in the rat. II. Distribution of the drug and its metabolites in various tissues in vivo and in the isolated perfused liver system. J Pharmacol Exp Ther 212:103-108, 1980.

15. Meyers M, W Slikker, G Pascoe and M Vore: Characterization of cholestasis induced by estradiol-17β-D-glucuronide in the rat. J Pharmacol Exp Ther 214:87-93, 1980.

16. Vore M and C Montgomery: The effect of estradiol-17β treatment on the metabolism and biliary excretion of phenytoin in the isolated perfused rat liver and in vivo. J Pharmacol Exp Ther 215:71-76, 1980.

17. Montgomery C and M Vore: The effect of diethylstilbestrol treatment on the metabolism and biliary excretion of [14C]phenytoin in the isolated perfused rat liver. Toxicol Appl Pharmacol 58:510-519, 1981.

18. Meyers M, W Slikker and M Vore: Steroid D-ring glucuronide: characterization of a new class of cholestatic agents in the rat. J Pharmacol Exp Ther 218:63-73, 1981.

19. Brock WJ and M Vore: Hepatic morphine and estrone glucuronyltransferase activity and morphine biliary excretion in the isolated perfused rat liver. Effect of pregnancy and estradiol-17 treatment. Drug Metab Dispos 10:336-343, 1982.

3

Mary Vore

Publications - Refereed Journals - Continued

20. Auansakul AC and M Vore: The effect of pregnancy and estradiol-17β treatment on the biliary transport maximum of dibromosulfophthalein, and the glucuronide conjugates of [14C]5-phenyl-5-parahydroxyphenylhydantoin and [14C]morphine in the isolated perfused rat liver. Drug Metab Dispos 10:344-349, 1982.

21. Slikker W, Jr, M Vore, JR Bailey, M Meyers and C Montgomery: Hepatotoxic effects of estradiol-17β-D-glucuronide in the rat and monkey. J Pharmacol Exp Ther 225:138-143, 1983.

22. Vore M, H Hadd and W Slikker, Jr: Ethynylestradiol-17β-D-ring glucuronide conjugates are potent cholestatic agents in the rat. Life Sci 32:2989-2993, 1983.

23. Brock W and M Vore: Characterization of uptake of steroid glucuronides into isolated male and female rat hepatocytes. J Pharmacol Exp Ther 229:175-181, 1984.

24. Brock W, S Durham and M Vore: Characterization of the interaction between estrogen metabolites and taurocholate for uptake into isolated hepatocytes. Lack of correlation between cholestasis and inhibition of taurocholate uptake. J Steroid Biochem 20:1181-1185, 1984.

25. Brock WJ and M Vore: The effect of pregnancy and treatment with estradiol-17β on the transport of organic anions into isolated rat hepatocytes. Drug Metab Dispos 12:712-716, 1984.

26. Potts Brian D, CA Martin and M Vore: Gas chromatographic quantitation of methylphenidate in plasma using solid-phase extraction and nitrogen sensitive detection. Clin Chemistry, 30:1374-1377, 1984.

27. Hamann SR, TG Tan, KE Kaltenborn, KLR Brouwer, RA Blouin, SL Chang, M Vore and RG McAllister, Jr: Effects of phenobarbital and SKF-525A on in vitro hepatic metabolism of verapamil and nifedipine. Pharmacology, 30:121-128, 1985.

28. Hamann SR, KE Kaltenborn, M Vore, TG Tan and RG McAllister: Cardiovascular and pharmacokinetic consequences of combined administration of verapamil and propranolol in dogs. Am J Cardiol 56:147-156, 1985.

29. Durham S, R Mack, III and M Vore: Effects of taurocholate infusion on biliary excretion in isolated perfused rat liver: Decreased biliary excretion of dibromosulfophthalein in pregnancy. Drug Metab Dispos 13:695-699, 1985.

30. Brouwer KLR and M Vore: The effect of hypoxia and pregnancy on antipyrine metabolism in isolated perfused rat liver. J Pharmacol Exp Ther 234:584-589, 1985.

31. Durham S and M Vore: Taurocholate and steroid glucuronides. Mutual protection against cholestasis in the isolated perfused rat liver. J Pharmacol Exp Ther 237:490-495, 1986.

32. Hughes MF, WJ Brock, LJ Marion and M Vore: Characterization of covalent binding of N-nitrosonornicotine in rat liver microsomes. Carcinogenesis 7:3-8, 1986.

33. Takacs A, A Auansakul, S Durham and M Vore: High and low affinity binding of [3H] cholate to rat liver plasma membranes. Biochem Pharmacol 36:2547-2555, l987.

34. Takacs A and M Vore: Binding of 3H-estradiol-17β(β-D-glucuronide), a cholestatic organic anion, to rat liver plasma membranes. Evidence consonant with identification of organic anion carriers. Mol Pharmacol 32:511-518, l987.

35. Brouwer KLR, S Durham and M Vore: Multiple carriers for uptake of 3H-estradiol-17β(β-D-glucuronide) in isolated rat hepatocytes. Mol Pharmacol 32: 519-523, l987.

36. Connors S and M Vore: Co-regulation of C3-OH vs C17-OH glucuronidation of 17β-estradiol in pregnancy and following treatment with phenobarbital or ethinyl-estradiol. J Pharmacol Exp Ther 246:54-59, 1988.

37. Vore M, C Montgomery, S Durham, D Schlarman and WH Elliott: Structure-activity relationship of the cholestatic activity of dihydrotestosterone glucuronide, allo bile acids and lithocholate. Life Sci 44:2033-2040, 1989.

38. Martin CA, M Vore, BD Potts, RJ Kryscio, JC Norton, JM Madigan, RJ Welsh, WM Heffron and JP Liu. Methylphenidate plasma concentrations in chronically and acutely treated latency-age children. Pharmacology, 39:46-49, 1989.

39. Ott MT, Vore M, Barker DE, Strodel WE and McClain CJ: Monokine Depression of Bile Flow in the Isolated Perfused Rat Liver. J Surgical Res 47:248-250, 1989.

4

Mary Vore

Publications - Refereed Journals Continued

40. Little K Y, Gay T L and Vore M: Predictors of Response to High Dose Antipsychotics in Chronic Schizophrenics. Psychiatry Research 30:1-9, 1989.

41. Teo S and M Vore: Mirex-induced inhibition of uptake of taurocholate and estradiol-l7β(β-D-glucuronide) in isolated hepatocytes. Toxicol Appl Pharmacol, 104:411-420, 1990.

42. Changchit A, S Durham and M Vore: Characterization of 3H-estradiol-17β(β-D-glucuronide) binding sites in basolateral and canalicular liver plasma membranes. Biochem Pharmacol, 40:1219-1225, 1990.

43. Vore M, S Durham, S Yeh and T Ganguly: Hepatic clearance and biliary secretory rate maximum of taurocholate in the recirculating and single pass isolated perfused rat liver: Effects of the cholestatic agent, estradiol 17β(β-D-glucuronide). Biochem Pharmacol, 4l(3):43l-437, 1991.

44. Teo S and M Vore. Mirex inhibits bile acid secretory function in vivo and in the isolated perfused rat liver. Toxicol Appl Pharmacol 109:161-170, 1991.

45. Zimniak P, SA Ziller III, I Panfil, A Radominska, H Wolters, F Kuipers, R Sharman, M Saxena, M Moslen, M Vore, R Vonk, Y Awasthi and R Lester. Identification of an anion-transport ATPase that catalyzes glutathione conjugate-dependent ATP hydrolysis in canalicular plasma membranes from normal rats and rats with conjugated hyperbilirubinemia (GY mutant)1. Arch Biochem Biophys 292(2):534-538, 1992.

46. Liu Y and M Vore. Prolactin stimulates maternal bile secretory function postpartum. J Pharmacol Exp Therap 261: 560-566, 1992.

47. Vore M. Canalicular Transport: Discovery of ATP-Dependent Mechanisms. Toxicol. Appl. Pharmacol. 118(1):2-7, 1993.

48. Bluhm RE, MG Frazer, M Vore, CW Pinson and KF Badr: Endothelins 1 and 3: Potent cholestatic agents secreted and excreted by the liver that interact with cyclosporine. Hepatology 18(4):961-968, 1993.

49. Ganguly T, JF Hyde and M Vore: Prolactin increases Na+/taurocholate cotransport in isolated hepatocytes from postpartum rats and ovariectomized rats. J Pharmacol Exp Therap 267(1):82-87, 1993.

50. Gosland M, C Tsuboi, T Hoffman, S Goodin and M Vore: Estradiol-17β glucuronide: An inducer of cholestasis and a physiological substrate for the multidrug resistance transporter. Cancer Res. 53:5382-5385, 1993.

51. Vore M, and T Hoffman: Carrier-mediated electrogenic transport of 3H-estradiol-17β (β-D-glucuronide) in rat liver basolateral membrane vesicles. Am. J. Physiol., G546-G551, 1994.

52. Ganguly, TC, Y Liu, J F Hyde, B Hagenbuch, PJ Meier and M Vore: Prolactin increases hepatic Na+/taurocholate cotransport activity and messenger RNA postpartum. Biochem J, 303:33-36, 1994. PMC1137552

53. Liu Y, T Ganguly, JF Hyde and M Vore: Prolactin increases mRNA encoding Na+/taurocholate (TC) cotransport polypeptide and hepatic Na+/TC cotransport. Am J Physiol, 268:G11-G17, 1995.

54. Albers KM, F Davis, T Perrone, E Lee, Y Liu and M Vore: Ectopic expression of a keratin intermediate filament protein in liver of transgenic mice causes alterations in structure and function. J Cell Biol, 128:157-169, 1995. PMC2120333

55. Vore M, T Hoffman and M Gosland: ATP-dependent transport of estradiol-17β-(β -D-glucuronide) in rat canalicular membrane vesicles. Am J Physiol, 271:G791-G798, 1996.

56. Kanai N, R Lu, Y Bao, AW Wolkoff, M Vore and VL Schuster: Estradiol 17-β-D-glucuronide is a high affinity substrate for the organic anion transporter "Oatp". Am J Physiol 270:F326-F331, 1996.

57. Liu, Y, L Huang, T Hoffman, M Gosland and M Vore: MDR1 substrate-modulators protect against estradiol l7 β-(β-D-glucuronide) cholestasis in the rat liver. Cancer Res. 56:4992-4997, 1996.

58. Liu Y, F Suchy, J Silverman and M Vore: Prolactin increases ATP-dependent taurocholate transport in canalicular plasma membranes from rat liver. Am J Physiol., 272:G46-G53, 1997.

5

Mary Vore

Publications - Refereed Journals - Continued

59. Ganguly TC, ML O’Brien, SJ Karpen, JF Hyde, FJ Suchy and M Vore. Regulation of the rat liver sodium-dependent bile acid cotransporter gene by prolactin. Mediation of transcriptional activation by STAT5. J Clin Invest 99:2906-2914, 1997. PMC508142

60. Martin CA, AG Mainous III, RO Mainous, MJ Oler, T Curry and M Vore. Progesterone and adolescent suicidality. Biol Psychiatry 42:956-958, 1997.

61. Huang L, T Hoffman and M Vore. ATP-dependent transport of estradiol-17-(-D-glucuronide) in membrane vesicles by MDR1 expressed in insect cells. Hepatology 28:1371-1377, 1998.

62. Luquita MG, VA Catania, EJ Sanchez-Pozzi, M Vore and AD Mottino. Prolactin increases the hepatic content of Yb subunits of glutathione S-transferase in the rat. Drug Metab Dispos 27:122-124, 1999.

63. Kline RM, Fennewald, Vore ME, Bertolone SJ, Hente ML. Oral contraceptives: A cause of hyperbilirubinemia in stem cell transplant patients. J Pediatric Hematology/Oncology 21: 436-440, 1999.

64. Luquita MG, Catania VA, Sanchez-Pozzi EJ, Vore M, Veggi LM, Pellegrino JM and Mottino AD. Induction of phase II biotransformation reactions in rat jejunum during lactation. Possible involvement of prolactin. Biochim Biophys Acta 1472:82-92, 1999.

65. Mottino AD, Hoffman T, Jennes L and Vore M. Expression and localization of the multidrug resistant protein mrp2 in rat small intestine. J Pharmacol Exp Therap 293:717-723, 2000.

66. Huang L and Vore M. Mrp2 is essential for estradiol-17(-D-glucuronide) induced cholestasis in rat. Hepatology 32:66-72, 2000.

67. Cao J, Huang L, Liu Y, Hoffman T, Stieger B, Meier PJ and Vore M. Differential regulation of hepatic bile salt and organic anion transporters in pregnant and postpartum rats and the role of prolactin. Hepatology 33: 140-147, 2001.

68. Gowri PM, Ganguly TC, Cao J, Devalaraja MN, Groner B and Vore M. Conversion of Threonine-757 to Valine enhances Stat5 transactivation potential J Biol Chem 276:10485-10491, 2001.

69. Mottino AD, Hoffman T, Jennes L, Cao J and Vore M. Expression of multidrug resistance-associated protein 2 in small intestine from pregnant and postpartum rats. Amer J Physiol 280: G1261-G1273, 2001.

70. Huang L and Vore M. Multidrug resistance P-glycoprotein 2 is essential for the biliary excretion of indocyanine green. Drug Metab Dispos 20:634-637, 2001.

71. Luquita M, Catania V, Sancehz-Pozzi E, Veggi L, Hoffman T, Pellegrino J, Ikushiro S-I, Emi Y, Iyanagi T, Vore M and Mottino A. Molecular basis of perinatal changes in UDP-glucuronosyltransferase activity in maternal rat liver. J Pharmacol Exp Ther 298: 49-56, 2001.

72. Oakley GG, Roe AL, Blouin RA, Twaroski TP, Ganguly TC, Vore M, Lehmler H-J and Robertson LW. 2,4,4’-Trichlorobiphenyl increases Stat5 transcriptional activity. Mol Carcinogenesis 30: 199-208, 2001.

73. Cao J, Gowri PM, Ganguly TC, Hyde JF, Talamantes F and Vore M. Prolactin, placental lactogen and growth hormone induce Na+/taurocholate cotransporting polypeptide gene expression by activating Stat5 in liver cells. Endocrinology 142(10): 4212-4222, 2001.

74. Kostrubsky VE, Vore M, Kindt E, Burliegh J, Rogers K, Peter G, Altrogge D and Sinz MW. The effect of troglitazone biliary excretion on metabolite distribution and cholestasis in transporter deficient rats. Drug Metab Dispos 29:1561-1566, 2001.

75. Mottino AD, Hoffman T, Dawson PA, Luquita MG, Monti JA, Sanchez-Pozzi EJ, Catania VA, Cao J and Vore M. Increased expression of the ileal apical sodium-dependent bile acid transporter in postpartum rats. Am J Physiol 282:G41-G50, 2002.

76. Mottino AD, Cao J, Veggi LM, Crocenzi F, Roma MG and Vore M. Altered localization and activity of canalicular Mrp2 in estradiol-17-D-glucuronide-induced cholestasis. Hepatology 35:1409-1419, 2002.

77. Cao J and Vore M. Expression of rat hepatic multidrug resistance-associated proteins and organic anion transporters in pregnancy. Am J Physiol 283:G757-G766, 2002.

6

Mary Vore

Publications - Refereed Journals - Continued

78. P Gerk and Vore M. Perspectives in Pharmacology. Regulation of expression of the multidrug resistance-associated protein 2 (mrp2) and its role in drug disposition. J Pharmacol Exp Therap 302:407-415, 2002.

79. Anakk S, Ku CY, Vore M and Strobel HW. Insights into gender bias: rat cytochrome P450 3A9. J Pharmacol Exp Therap : 305 (2):703-709, 2003

80. Crocenzi FA, Mottino AD, Pellegrino JM, Rodríquez Garay EAR, Miliewicz P, Vore M, Coleman R and Roma MG. Impaired localization and transport function of canalicular bsep in taurolithocholate-induced cholestasis in the rat. Gut 52: 1170-1177, 2003. PMC1773741

81. Crocenzi F, Mottino AD, Cao J, Veggi LM, Sánchez Pozzi EJ, Vore M, Coleman R and Roma MG. Estradiol-17β-D-glucuronide induces endocytic internalization of Bsep in rats. Amer J Physiol 285: G449 – G459, 2003.

82. Mottino AD, Veggi LM, Wood M, Román JMV and Vore M. Biliary secretion of glutathione in estradiol 17β-D-glucuronide-induced cholestasis. J Pharmacol Exp Therap 307:306-313, 2003.

83. Cao J, Wood M, Liu Y, Hoffman T, Hyde J, Park-Sarge O-K, and Vore M. Estradiol represses prolactin-induced expression of Na+/taurocholate cotransporting polypeptide through estrogen receptor-α and Signal transducers and activators of transcription 5a in liver cells. Endocrinology 145:1739-1749, 2004.

84. Gerk PM, Li W, and Vore M. Estradiol 3-glucuronide is transported by the multidrug resistance-associated protein 2 (Mrp2) but does not activate the allosteric site bound by estradiol 17-glucuronide. Drug Metab Dispos 32:1139-1145, 2004.

85. Mottino AD, Crocenzi FA, Sánchez Pozzi EF, Veggi LM, Roma MG and Vore M. Role of microtubules in estradiol-17β-D-glucuronide-induced alteration of canalicular Mrp2 localization and activity. Amer J Physiol 288(2):G327-36,2005. Epub 2004 Sep 16..

86. Ruiz ML, Villanueva SSM, Luquita MG, Sánchez-Pozzi EJ, Crocenzi FA, Pellegrino JM, Ochoa JE, Vore M, Mottino AD and Catania, VA. Mechanisms involved in spironolactone-induced choleresis in the rat. Role of multidrug resistance-associated protein 2. Biochem Pharmacol 69:531-539, 2005

87. Wood M, Ananthanarayanan M, Jones B, Wooton-Kee R, Hoffman T, Suchy JF and Vore M. Hormonal regulation of hepatic organic anion transporting polypeptides. Mol Pharmacol 68:218-225, 2005. Apr 19; [Epub ahead of print] PMID: 15840840 PMC1463998

88. Joshi G, Sultana R, Tangpong J, Cole MP, St. Clair DK, Vore M, Estus S, and Butterfield DA. Free Radical Mediated Oxidative Stress and Toxic Side Effects in Brain Induced by the Anti Cancer Drug Adriamycin:  Insight into Chemobrain.  Free Radical Research 39: 1147-1154, 2005.

89. Jones B, Li W, Cao J, Hoffman T, Gerk P, and Vore M. The role of protein synthesis and degradation in the posttranscriptional regulation of rat multidrug resistance-associated protein 2 (Mrp2, Abcc2). Mol Pharmacol, 68:701-710, 2005 doi: 10.1124/mol.105.013144 May, 2005

90. Ghanem CI, Ruiz ML, Villanueva SS, Luquita MG, Catania VA, Jones B, Bengochea LA, Vore M, and Mottino AD. Shift from biliary to urinary elimination of acetaminophen glucuronide in acetaminophen pretreated rats. J Pharmacol Exp Ther 315:987-995, 2005

91. Mottino AD, Carreras FI, Gradilone SA, Marinelli RA and Vore M. Canalicular membrane localization of hepatocyte aquaporin-8 is preserved in estradiol-17β-D-glucuronide–induced cholestasis. J Hepatol. 44: 232-233, 2006.

92. Tangpong J, Cole MP, Sultana R, Joshi G, Estus S, Vore M, St.Clair W, Ratanachaiyavong S, St. Clair D and Butterfield DA. Adriamycin-induced, TNF-α-mediated central nervous system toxicity. Neurobiology of Disease. 23: 127-139, 2006.

93. Ruiz ML, Villanueva SSM, Luquita MG, Vore M, Mottino AD and Catania VA. Ethinylestradiol increases expression and activity of rat liver Mrp3. Drug Metab Dispos 34(6): 1030-1034, 2006.

94. Tangpong J, Cole MP, Sultana R, Estus S, Vore M, St.Clair W, Ratanachaiyavong S, St.Clair DK and Butterfield DA. Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: Insight into the mechanism of chemobrain. J Neurochem, 100:191-201, 2006.

7

Mary Vore

Publications - Refereed Journals - Continued

95. Chen Y, Daosukho, Opii WO, Turner DM, Pierce WM, Klein JB, Vore M, Butterfield DA and St. Clair DK. Redox proteomic identification of oxidized cardiac proteins in adriamycin-treated mice. Free Rad Biol Med 41:1470 – 1477, 2006.

96. Jungsuwadee P, Cole MP, Sultana R, Joshi G, Tangpong J, Butterfield DA, St. Clair DK, and Vore

M. Increase in Mrp1 expression and 4-hydroxy-2-nonenal adduction in heart tissue of Adriamycin-treated C57Bl/6 mice. Mol Cancer Ther 5(11): 2851 – 2860, 2006.

97. Joshi G, Hardas S, Sultana R, St Clair DK, Vore M and Butterfield DA. Glutathione elevation by gamma-glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by in vivo administration of Adriamycin: Implication for chemobrain. J Neurosci Res 85:497-503, 2006. Epub ahead of print PMID 17171703.

98. Gerk PM, Li W, Megaraj V and Vore M. Human multidrug resistance protein 2 (MRP2/ABCC2) transports the therapeutic bile salt tauroursodeoxycholate. J Pharmacol Exp Ther 320:893 – 899, 2007. (EPub ahead of print 11/15/2006, PMID 17108237.

99. Zhang Y, Li W, and Vore M. Translational regulation of rat multidrug resistance-associated protein 2 (Mrp2) expression is mediated by upstream open reading frames in the 5' untranslated region (UTR). Mol Pharmacol 71:377-383, 2007.

100. Mottino A, Hoffman T, Crocenzi F, Sanchez Pozzi E, Roma M and Vore M. Disruption of function and localization of tight-junctional structures and Mrp2 in sustained estradiol-17β-D-glucuronide-induced cholestasis. Am J Physiol Gastrointest Liver Physiol 293(1):G391-402, 2007. PMID: 17463180

101. Chen Y, Jungsuwadee P, Vore M, Butterfield DA and St. Clair DK. Collateral Damage in Cancer Chemotherapy: Oxidative Stress in Nontargeted Tissues. Mol. Interv 7: 147-156, 2007.

102. Wooton-Kee C, Cohen DE and Vore M. Increased cholesterol 7α-hydroxylase expression and size of the bile acid pool in the lactating rat. Am J Physiol Gastrointest Liver Physiol. 294: G1009 – G1016, 2008. PMC2408447

103. Tangpong J, Sompol P, Vore M, St Clair W, Butterfield DA, St Clair DK. Tumor necrosis factor α-mediated nitric oxide production enhances manganese superoxide dismutase nitration and mitochondrial dysfunction in primary neurons: an insight into the role of glial cells. Neuroscience 151:622-629, 2008.

104. Crocenzi FA, Sánchez Pozzi EJ, Ruiz ML, Zucchetti AE, Roma MG, Mottino AD and Vore M. Ca2+-Dependent protein kinase C isoforms are critical to estradiol-17β-D-glucuronide-induced cholestasis in the rat. Hepatology 48(6): 1885-1895, 2008. PMC3004396

105. Jungsuwadee P, Nithipongvanitch R, Chen Y, Tangpong J, Oberley T, Butterfield A, St.Clair D and Vore M. Mrp1 Localization and Function in Cardiac Mitochondria Following Doxorubicin. Mol Pharmacol 75:1117-1126, 2009. PMC2672805

106. Arias A, Villanueva SSM, Ruiz ML, Luquita MG, Veggi LM, Pellegrino JM, Vore M, Catania VA, and Mottino AD. Regulation of expression and activity of rat intestinal Mrp2 by cholestatic estrogens. Drug Metab Dispos 37:1277-1285, 2009.

107. Aluise CD, St. Clair D, Vore M, Butterfield DA. In vivo amelioration of Adriamycin induced oxidative stress in plasma by gamma-glutamylcysteine ethyl ester (GCEE). Cancer Lett 282: 25-29, 2009.

108. Wooton-Kee CR, Coy DJ, Athippozhy AT, Zhao T, Jones BR, and Vore M. Mechanisms for increased expression of cholesterol 7α-hydroxylase (Cyp7a1) in lactating rats. Hepatology 51(1): 277-285, 2010. PMC2799537

109. Zhang Y, Zhao T, Li W and Vore M. The 5'-untranslated region of multidrug resistance associated protein 2 (MRP2; ABCC2) regulates downstream open reading frame expression through translational regulation. Mol Pharmacol 77:327-246, 2010. PMC2812073

8

Mary Vore

Publications - Refereed Journals - Continued

110. Joshi G, Aluise CD, Cole MP, Sultana R, Pierce WM, Vore M, St. Clair DK, Butterfield DA. Alterations in brain antioxidant enzymes and redox proteomic identification of oxidized brain proteins induced by the anti-cancer drug adriamycin: implications for oxidative stress-mediated chemobrain. Neuroscience 166:796-807, 2010. PMID 20096337 PMC2852883

111. Coy DJ, Wooton-Kee C, Yan B, Sabeva N, Su K, Graf G and Vore M. ABCG5/ABCG8-Independent biliary cholesterol excretion in lactating rats. Am J Physiol Gastrointest Liver Physiol: 299(1):G228-35, 2010. PMID: 20413720 PMC2904104

112. Megaraj V, Iida T, Jungsuwadee P, Hofmann AF and Vore M. Hepatobiliary disposition of 3α,6α,7α,12α-tetrahydroxy-cholanoyl taurine : A substrate for multiple canalicular transporters. Drug Metab Dispos 38(10):1723-30, 2010. PMC2957170

113. Boaglio AD, Zucchetti AE, SánchezPozzi EJ, Pellegrino JM, Ochoa JE, Mottino AD, Vore M, Crocenzi FA and Roma MG. Phosphoinositide 3-kinase/protein kinase B signaling pathway is involved in estradiol 17β-D-glucuronide-induced cholestasis: Complementarity with classical protein kinase C. Hepatology. 52: 1465-76, 2010. PMID: 20815017

114. Villanueva SSM, Arias A, Ruiz ML, Rigalli JP, Pellegrino JM, Vore M, Catania VA and Mottino AD. Induction of intestinal multidrug resistance-associated protein 2 by glucagon-like peptide-2 in the rat. J Pharmacol Exp Ther. 335(2):332-41, 2010.

115. Athippozhy A, Huang L, Wooton-Kee CR, Zhao T, Jungsuwadee P, Stromberg AJ, and Vore M. Differential gene expression in liver and small intestine from lactating rats compared to age-matched virgin controls detects increased mRNA of cholesterol biosynthetic genes. BMC Genomics 12 (1):95, 2011. PMC3045338

116. Velez JM, Miriyala S, Nithipongvanitch R, Noel T, Plabplueng CD, Oberley T, Jungsuwadee P, Van Remmen H, Vore M and St. Clair DK. p53 regulates oxidative stress-mediated retrograde signaling: A novel mechanism for chemotherapy-induced cardiac injury. PLoS ONE 6(3):e18005 2011 Mar 30. PMC3068154

117. Aluise CD, Miriyala S, Noel T, Sultana R, Jungsuwadee P, Taylor TJ, Cai J, Pierce WM, Vore M, Moscow JA, St. Clair DK, and Butterfield DA. 2-Mercaptoethanesulfonate (MESNA) prevents doxorubicin (Dox)-induced plasma protein oxidation and TNF release: Implications for the reactive oxygen species-mediated mechanisms of chemobrain. Free Rad Biol Med 50:1630-1638, 2011.

118. Megaraj V, Zhao T, Paumi CM, Gerk PM, Kim RB and Vore M. Functional analysis of non-synonymous single nucleotide polymorphisms of multidrug resistance protein 2 (MRP2; ABCC2). Pharmacogenet Genomics. 21:506-515, 2011.

119. Jungsuwadee P, Zhao T, Stolarczyk EI, Paumi CM, Butterfield DA, St.Clair DK and Vore M. The G671V variant of MRP1/ABCC1 links doxorubicin-induced acute cardiac toxicity to disposition of the glutathione conjugate of 4-hydroxy- 2-trans-nonenal. Pharmacogenet Genomics 22(4):273-84, 2012. PMID: 22293538

120. Villanueva SSM, Perdomo VG, Ruiz ML, Rigalli JP, Arias A, Luquita MG, Vore M, Catania VA and Mottino AD. Effect of Glucagon-like Peptide 2 on Hepatic, Renal, and Intestinal Disposition of 1-chloro-2,4-dinitrobenzene. Drug Metab Dispos 40:1252-1258, 2012; Epub ahead of print March 27, 2012.doi:10.1124/dmd.111.044339

9

Mary Vore

Publications - Refereed Journals - Continued

121. Zhang Y, Li F, Patterson A, Wang Y, Kraubsz K, Neale G, Thomas S, Nachagari D, Vogel P, Vore M, Gonzalez FJ and Schuetz J. Abcb11 Deficiency Induces Cholestasis Coupled to Impaired β-Fatty Acid Oxidation in Mice. J Biol Chem 287:24784-27494, 2012. May 22. [Epub ahead of print] PMID: 22619174

122. Ruiz ML, Rigalli JP, Arias A, Villanueva S, Banchio C, Vore M, Mottino AD and Catania VA. Induction of hepatic multidrug resistance associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor. Drug Metab Dispos 41(2):275-80, 2013. Published online October 17, 2012 doi:10/1124/dmd.112.047357

123. Zhao T, Zhang Y, Yan B, Thompson SR and Vore M. Translation of multidrug resistance protein 2 (MRP2, ABCC2) is regulated by insulin-like growth factor 2 mRNA binding protein 1. In revision

124. Thomas TC, Noel T, Jungsuwadee P, Butterfield DA, St. Clair DK, Vore M, Gerhardt GA. Treatment with Doxorubicin Affects Glutamate Neurotransmission in the Prefrontal Cortex and Hippocampus. In revision.

10

Mary Vore

Chapters In Books, Reviews

1. MT Bush, HJ Sekerke, M Vore, BJ Sweetman and JT Watson: Proc. Seminar on the Use of Stable Isotopes in Clinical Pharmacology Conf. No. 71117, pp. 233-237. Technological Information Center, Washington, D.C. (1971).

2. Lu, AYH, W Levin, SB West, M Vore, D Ryan, R Kuntzman and AH Conney: Role of Cytochrome b5 in NADPH- and NADH-dependent hydroxylation by the reconstituted cytochrome P-450 or P-448 containing system. Cytochromes P - 450 and b 5 eds. D.Y. Cooper, O. Rosenthal, R. Snyder and C. Witmer, Plenum Publishing Corp., New York, 1975, pp. 447-466.

3. Lu, AYH, W Levin, M Vore, AH Conney, DR Thakker, G Holder and DM Jerina: Carcinogenesis, Vol. 1. Polynuclear Aromatic Hydrocarbons: Chemistry, Metabolism and Carcinogenesis, edited by R.I. Freudenthal and I.W. Jones, Raven Press, New York, 1976, pp. 115-126.

4. Regulation of mixed-function oxidase activity by membrane lipids. M. Vore and P.J. Hakkinen: Microsomes, Drug Oxidations and Chemical Carcinogenesis. Ed. M.J. Coon, A.H. Conney, R.W. Estabrook, H.V. Gelboin, J.R. Gillette and P.J. O'Brien, Academic Press, New York, 1980. pp. 541-544.

5. Vore M, C Montgomery and M Meyers: Steroid D-ring glucuronides: Characterization of a new class of cholestatic agents. Drug Metabolism Reviews, 14(5), 1005-1019 (1983).

6. Vore M and W Slikker: Steroid D-Ring Glucuronides: A new class of cholestatic agents. Trends in Pharmacological Sciences, 6:256-259, 1985.

7. Vore M and WR Martin: Common Adverse Drug Interactions. Hospital Publications, Inc., 22(10):94-110, 1986.

8. Vore M: Estrogen Cholestasis: Membranes, Metabolites or Receptors? Gastroenterology, 93(3):643-649, l987.

9. Vore M, A Changchit, S Durham and S Teo: Transport properties of steroid glucuronides In: Hepatic Transport of Organic Substances Springer-Verlag, Heidelberg, 1989. Editors: E. Petzinger, R.K.H. Kinne and H. Sies, pp. 377-387.

10. Vore, M: Mechanisms of Cholestasis. In: Hepatotoxicology. Editors: RG Meeks and SD Harrison. CRC Press, Boca Raton, FL pp 525-568, 1991.

11. Vore M: Biliary Excretion of Drugs and Other Chemicals. Editors: C-P Siegers and JB Watkins, III. In: Progress in Pharmacology and Clinical Pharmacology, Gustav Fischer Verlag, Stuttgart 4(8):1991, pp 455-473.

12. Vore M: Regulation of Drug Conjugate Processing by Hepatocellular Transport Systems. In: Handbook of Experimental Pharmacology Ed: FC Kauffman. Springer-Verlag 112(11):311-38, 1994.

13. Vore M: Editorial: Phase III Elimination: Another Two-Edged Sword. In: Environmental Health Perspectives 102(5):422-423, 1994. PMC1567152

14. Vore M, Y Liu and TC Ganguly. Isolated Hepatocytes. In: Models for Assessing drug Absorption and Metabolism. Ed: RT Borchardt, PL Smith, G Wilson, Plenum Press, New York, pp 115-121, 1996.

11

Mary Vore

Chapters In Books, Reviews - Continued

15. Vore M, Y Liu and T Ganguly. Prolactin and Bile Secretory Function. In: Pregnancy, Sex Hormones and the Liver. Ed: HB Reyes, U Leuschner, IM Arias. Falk Symposium 89, Kleuver Academic Publishers, Netherlands, pp 77-83, 1996.

16. M Vore. Mechanisms of Cholestasis: Steroid Glucuronides as a Model. Toxicologic Pathol. 24:386-387, 1996

17. Vore M, Y Liu and L Huang. Cholestatic Properties and Hepatic Transport of Steroid Glucuronides. Drug Metabolism Rev 29 (1&2):193-203, 1997.

18. Vore M and KLR Brouwer. Cholestatic Properties of Steroid Glucuronides. In: Toxicology of the Liver. Eds: GL Plaa and WR Hewitt. Taylor & Frances, Washington, DC pp 323-346, 1998.

19. Gerk P and Vore M. Multidrug resistance proteins and hepatic transport of endo- and xenotbiotics. In Drug Metabolism and Transport: Molecular Methods and Mechanisms. Ed: Larry H. Lash. Humana Press, Inc. pp 273-289, 2004.

19. Comments on Toxicology, Special Issue: Impact of Multidrug Resistance Associated Protein 2 (Mrp2) 9: (3-4), pp 197 – 200, 2003. Guest Editor for Issue

20. Vore M and Gerk P. Activation of MRP2 transport by ursodeoxycholic acid (UDCA) and its amidates. XVIII International Bile Acid Meeting. Falk Symposium 141. Bile Acid Biology and its Therapeutic Implications, pp175-180, 2005.

21. Vore, Mary and Gerk, Phil. Active Transport of Drugs Across Membranes,. XPharm (2004); Executive Editors: SJ Enna and David B Bylund; Elsevier, Inc., New York. http://www.xpharm.com/citation?Article_ID=107

22. Gerk PM and Vore M. Viewpoint: The ileocyte basolateral organic solute transporter (OSTα-OSTβ) complex: Finding the missing link in enterohepatic circulation. Mol Interventions 5:8-10, 2005.

23. Member of a Panel: Golub M, Costa L, Crofton K, Frank D, Fried P, Gladen B, Hnderson R, Liebelt E, Lusskin S, Marty S, Rowland A, Scialli J, Vore M. NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of amphetamine and methamphetamine. Birth Defects Res B Dev Reprod Toxicol. 74(6): 471 – 584, 2005.

24. Member of a Panel: Golub M, Costa L, Crofton K, Frank D, Fried P, Gladen B, Henderson R, Liebelt E, Lusskin S, Marty S, Rowland A, Scialli J, Vore M. NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of methylphenidate. Birth Defects Res B Dev Reprod Toxicol. 74(4):300-81, 2005.

25. Vore M and Leggas M. Commentary: Progesterone acts via Progesterone Receptors A and B to Regulate BCRP Expression. Mol Pharmacol 73:613-615, 2008.

26. Jungsuwadee P and Vore M. Efflux Transporters in Comprehensive Toxicology, Editor-in-Chief, Charlene A. McQueen. Volume 4, Biotransformation, Editor, F. Peter Guengerich. Elsevier. 2010 Second Edition, Chapter 26, pp 557 – 601.

12

Mary Vore

Chapters In Books, Reviews - Continued

27. Aluise CD, Sultana R, Tanpong J, Vore M, St.Clair D, Moscow JA and Butterfield DA. Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: Role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction. In Chemo-fog Cancer Chemotherapy-related cognitive impairment. Adv Exptl Med Biol 678: 147-156, 2010. Ed Robert B. Raffa and Ronald J. Tallerida, Landes Bioscience/Springer Science Austin, TX. Review.PMID: 20738017 [PubMed - indexed for MEDLINE]

28. Jungsuwadee P, Vore M and St. Clair DK. Chemotherapy-induced oxidative stress in nontargeted normal tissues. In Oxidative stress in Cancer Biology and Therapy. Humana Press, 97-129, 2012. Ed: DR Spitz, KJ Dornfeld, K Krishnan and D Gius.

13

Mary Vore

Recent Presentations/Abstracts (not yet published as peer-reviewed ms):

Mary Vore, Tianyong Zhao. The -24 C>T SNP in MRP2 affects the binding of transacting factors to an RNA motif in MRP2 5'UTR and decreases translation of the downstream open reading frame (ORF). Presented at the 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD), November 4-8, 2011. San Francisco, CA. Hepatology 54: 723A, 2011.

Donna J Coy1, Paiboon Jungsuwadee1, Teresa Noel1, Luksana Chaiswing2, Terry Oberley2, Daret St. Clair1 and Mary Vore1. Mrp1 protects against Doxorubicin induced cardiotoxicity. The FASEB Journal 26:1050.1, 2012. (1 Graduate Center for Toxicology, University of Kentucky; 2 Pathology and Laboratory Medicine, University of Wisconsin-Madison).

14

Mary Vore

Teaching1. Students/Postdoctoral Fellows Trained

Dr. Daniel R. Goodman, Ph.D. conferred 6/19/77Assistant Professor of Pharmacology and Toxicology,University of Arkansas, Little Rock, AR Deceased, 8/1983

Dr. Michael B. Aufrere, Ph.D. conferred 6/19/78Toxicologist, Standard Oil of California, Richmond, CA Deceased, 10/1983

Dr. Pertti Juhani Hakkinen, Ph.D. conferred 9/12/79Postdoctoral Fellow with Dr. Hanspeter WitschiPresent position: Toxicologist with the National Library of Medicine

Dr. Christopher Montgomery, M.S. conferred 6/81M.D. Degree, 1985; University of KentuckyPresent position: Associate Professor, Department of Anesthesiology, College of Medicine, University of Kentucky, Lexington, KY

Dr. Mark Meyers, Ph.D. conferred 8/81Present position: Hospital Pharmacist, Spokane, Washington

Dr. Arunee Changchit, Ph.D. conferred 5/82Postdoctoral Fellow: 1987-1988Most recent position: Vice President for Drug Metabolism, Neurogen, Inc. Branford, CT 06405; now retired.

Dr. William Brock, Ph.D. conferred 4/83Present position: Toxicology Consultant

Mr. Brian Potts, MS conferred 12/84Present position: Analytical Scientist, Eli Lilly, Indianapolis, IN

Dr. Adrienne Takacs, Ph.D. conferred 8/85Director, Drug Disposition Lead Optimization, Eli Lilly Co, Indianapolis, IN

Dr. Michael Hughes, Ph.D. conferred 6/86Present Position: Project Scientist, Environmental Protection Agency,Research Triangle Park, NC

Dr. Mary Suzanne Connors, Ph.D. conferred 10/86Consultant in Toxicology

Dr. Kim Rowse-Brouwer, Postdoctoral Fellow: 1983-1986 Present Position: Professor and Chair, College of Pharmacy, University of North Carolina

Dr. Steve Teo, Ph.D. conferred 12/89Present Position: Manager, Pharmacokinetics and Toxicology, Celgene Corp,Warren, NJ

Dr. Tanmoy Ganguly, Ph.D. conferred 3/94Present position: Senior Scientist III, Momenta Pharmaceuticals, Cambridge, MA

15

Mary Vore

Teaching, continued

Dr. Yong Liu, Ph.D. conferred 8/96Present position: Clinical Pharmacology, Celgene Summit, NJ

Dr. Liyue Huang, Ph.D. conferred 8/99Present position: Amgen, Boston, MA

Dr. Jingsong Cao, Postdoctoral Fellow: 1999-2002Present Position: Lab Head, Investigator III, Cardiovascular and Metabolic Diseases, USCA 6017302, Novartis Institutes for BioMedical Research, Inc, 100 Technology Square, Cambridge, MA 02139

Dr. Mangala Gowri, Postdoctoral Fellow: 1997-2000Present Position: Department of Molecular and Integrative Physiology, University of Illinois, Champagne-Urbana

Dr. Wei Li, Postdoctoral Fellow: 2000 – 2002Present position: Department of Medicine, University of Kentucky

Dr. Phil Gerk, Postdoctoral Fellow: 2000-2004Present position: Associate Professor, Dept of Pharmaceutics, School of Pharmacy, VCU, Richmond, VA

Dr. Brett Jones, Postdoctoral Fellow: 2004 - 2007Staff Toxicologist, ILS,Inc./Contractor supporting the NTP Interagency for the Evaluation of Alternative Toxicological Methods (NICEATM), RTP, NC

Dr. Marcie Wood, Ph.D. conferred 12/2004Present position: FDA

Dr. Yuanyuan Zhang, PhD conferred 12/2008Postdoctoral Fellow, Dr. John Schuetz, St. Jude Research Hospital, Memphis, TN

Dr. Clavia Ruth Wooton-Kee, PhD conferred 12/2008Present position: Postdoctoral Fellow, Dr. David Moore, Baylor College of Medicine, Houston TX

Dr. Vandana Megaraj, PhD conferred 8/2010Present position: Postdoctoral Scholar, Dr. Xinxin Ding, Department of Public Health, Albany, NY

Dr. Paiboon Jungsuwadee, Postdoctoral Fellow/Scientist II, Research Assistant ProfessorAssistant Professor, College of Pharmacy, Roosevelt University, Schaumberg, IL

Dr. Antony Athippozhy, PhD conferred 8/2011Present Position: Postdoctoral Fellow, Dr. Randall Voss, Biological Sciences, UK

Dr. Donna J Coy, PhD conferred 12/2012Present Position: Scientist/Research and Development, Forensic Fluids, Kalamazoo, MI.

1 Ph.D. students currently: Wei Zhang1 Postdoctoral Fellow: Dr. Jun Deng1 Scientist I: Dr. Caixia Hou

16

Mary Vore

Teaching - continued

2. Served on Dissertation Committees of ~90 students in Ph.D. degree programs in Toxicology, Pharmacology, Chemistry, Physiology and Pharmaceutical Sciences.

Member of Ph.D. Advisory Committee (2011-2012)Kuei-Ling Kuo – Pharmaceutical Sciences Vasu Bakthavatchalu - ToxicologyNikhil Hebbar – Toxicology Cassie Reiling – Toxicology

3. Lecturesl975-l978 University of California, San Francisco

Lectures in Toxicology to Pharmacy studentsLectures to Graduate Students in Pharmacology and Toxicology on Toxicological testing methods, Biochemical Mechanisms of Toxicity, Chemical Carcinogenesis, Drug Metabolism.

l978-Present : University of KentuckyPHA821: Medical Pharmacology Lectures: Drug Metabolism, Pharmacokinetics, Antibiotics, Clinical Pharmacology. (15 contact hr - until 1993); Course Director: 1983-1993; 7 contact hr, 1995-97

PHA 663: Drug Metabolism and DispositionCourse Director and major instructor; 48 contact hoursTaught 15-20 students every other year from 1979 - 1999

PHA 522: Systems PharmacologyLectures in Drug Metabolism and Antibiotics; 7 contact hr until 1994Lectures in Drug Metabolism, 4 contact hours, 1995-1997; 2 contact hr - 1998

TOX 680: Molecular Mechanisms of ToxicityLectures on Hepatotoxicity and Mechanisms of Cholestasis 2-3 Contact hr 1980 – 1996Lecture on Alcoholic Liver Disease, 1 hr 2008-present.

TOX 509: Biochemical and Environmental Toxicology Course Co-Director: 1996 - 2011Pharmacokinetics – 5 hours; 2004-2007Lectures on metabolism, elimination, cholestasis: 6 h, 1997 – 2008; 3 h 2009 - Present

TOX 600: Ethics in Scientific ResearchCourse Director: 1998; Lecture and case discussion – 2000, 2002-4; 2009 - Present.

PHA 621: Principles of Drug ActionLecture: Role of transporters in Drug Disposition and Excretion 2008 – Present: 1 h

TOX 700-002: Toxicology Journal ClubCourse Director: 1998- 2002

Director of Graduate Studies, Graduate Center for Toxicology: 1998 - 2002

University ServiceInstitutional Self-Study - Objectives Subcommittee, 1979Task Force on Education - 1980-81Biochemistry Department Chairman's Search Committee - 1982-83University Service - continued

17

Mary Vore

College of Medicine Research Committee - Member: 1980-1984, Chairman: 1982-1984Faculty Council, 1985-86; Chairman 1986-87Institutional Cancer Review Committee, Chairman, 1985-87Search Committee, Dean, College of Pharmacy, 1986-87Chairman, Department of Biochemistry Review Committee, 1986Department of Anesthesiology Review Committee, 1985Department of Psychiatry Review Committee, 1986-87Department of Pathology Review and Chairman Search Committee, 1987-88LCME Steering Committee, 1987-89Tobacco and Health Institute - Technical Advisory Committee, 1988-89Committee on Appointments, Promotion and Tenure, 1986-89; Chair, l988-89Graduate Council, l988-90Curriculum Committee, College of Medicine, 1989-1992University Research Advisory Committee, Medical Center, 1989-1993Search Committee, Biochemistry Department Chairman, 1990 Chairman, Search Committee for Vice Chancellor for Research and Graduate Studies, Medical Center,

1990Robert Wood Johnson Steering Committee, 1990-1994Search Committee, Vice-President for Research and Graduate Studies, l994Environmental Health and Safety Committee, 1994-1996Taskforce on Research and Graduate Education, 1997Biological Sciences Faculty Search Committee, 1997; 1999Markey Cancer Center, Internal Advisory Committee, 1997- 2000Center for Applied Energy Research, Advisory Board, 1996-2001EPA Environmental EPSCoR, Subcommittee, 1997-1999Chair, Department of Microbiology and Immunology Review Committee, 2000Chair, Provost’s Incentive Program Review Committee – 2003Cancer Center Review Committee, 2003-4Search Committee, Director, Martin School, 2004Search Committee, Director, Markey Cancer Center, 2006-2009LCME Steering Committee and Chair of Educational Resources Subcommittee, 2009 – 2010Chair, College of Pharmacy Review Committee 2011CTTS TEAM Co-Leader; 2008-PresentMCC Co-Leader Redox Injury and Repair Program; 2010 – PresentCollege of Pharmacy Chair of Pharmaceutical Sciences Search Committee; 2011-2012Chair, Faculty Search Committee; MCC Lung Cancer and Oxidative Stress/DNA repair; 2011- Present

Professional ActivitiesA) Co - chaired and organized symposia : ASPET

1980: The Role of Nitrogen in Chemical Biotransformations and Drug Toxicity and The Role of Sulfur in Chemical Biotransformations and Drug Toxicity1984: Stable Isotopes and Drug Oxidation Studies1992: FASEB: Hepatic Transport Mechanisms 1995: FASEB: P-Glycoprotein: Physiologic and Biochemical Functions, Regulation and Clinical

Implications2002: Experimental Biology Meeting, Co-chair and Speaker: ASPET Symposium on Advances in

Understanding Transport of Drugs and Toxicants; Regulation of hepatic transport of drugs and toxicants. April 24

B) Gordon Research Conference on Drug Metabolism:Vice-Chairman (1981) and Chairman (1982) Chairman/Speaker: 1989, Speaker/Chair; 1992, 1994, 1998 - Session Chairman; 1996 – Speaker

18

Mary Vore

2002: Gordon Research Conference on Drug Metabolism, July 14-19: Regulation of expression and function of Mrp2.

Professional Activities – continued

C) Invited Speaker: (Recent Invitations) 2000: Toxicology Scholars Colloquium: University of Connecticut, Center for Biochemical Toxicology,

March 10. “Mechanisms of Regulation of Hepatic Drug Elimination in Pregnancy and Postpartum”

2000: Department of Pharmacology and Toxicology, University of Indiana, May 12. “Hormonal Regulation of Hepatic Transport Systems in Pregnancy and Postpartum”.

2000: Chair Symposium at ISSX, October 23-25; Xenobiotic Metabolism: The Role of ABCTransporters in Disposition of Xenobiotics; Presentation: Regulation of Expression of Mrp2 in Pregnancy and Postpartum.

2000: Pediatric Symposium: Maternal-Fetal Issues in Liver Diseases, NASPGN, October, 27. Liver Physiology in Pregnancy

2001: College of Pharmacy, University of Toronto; Hormonal Regulation of Hepatic Organic Anion and Bile Salt Transporters. March 13.

2001: Pfizer Research and Development; Hormonal Regulation of Hepatic Transport of Organic Anions; August 9.

2001: Department of Pharmacology and Toxicology, University of Kansas; Hormonal Regulation of Hepatic Organic Anion Transporters; December 4.

2002: Department of Pharmacology, Marshall University: Hormonal Regulation of Hepatic Organic Anion Transporters; February 25.

2002: Department of Physiology, University of Cincinnati: Role of prolactin in regulation of bile acid transport. April 10.

2004: Department of Pathology, U Texas Medical Branch, Galveston; March 8. Hormonal regulation of hepatic transporters.

2004: Department of Biochemistry and Molecular Pathology, NEOUCOM, Rootstown, OH.Hormonal regulation of bile acid transport during pregnancy and lactation. April 7.

2004: XVIII International Bile Acid Meeting, Stockholm (Sweden), June 18-19, 2004. Activation of MRP2 transport by ursodeoxycholic acid (UDCA) and its amidates.

2004: Department of Biochemistry and Molecular Biology, University of Arkansas, Little Rock, AK. Regulation of hepatic organic anion transporters. November 17.

2005: Department of Cardiology, University of Louisville, KY. Hormonal regulation of hepatic organic anion transporters. Feb 21.

2005: University of Washington, Seattle: Department of Obstetrics and Gynecology: Role of Transporters in Intrahepatic Cholestasis of Pregnancy (ICP) (March 2)Department of Pharmaceutics, College of Pharmacy: Regulation of Hepatic Organic Anion Transporters in Pregnancy and Postpartum (March 3)Department of Medicine, GI Division: Mechanisms of Regulation of Hepatic Organic Anion Transport (March 4)

2005: Digestive Disease Week, May 14-19, 2005. Invited speaker, Symposium: Pregnancy and the Liver; Hepatic Organic Anion Transport and Drug Disposition in Pregnancy.

2005: Gordon Research Conference on Multidrug Efflux Systems, Aug 28-Sept 2. Oxford, UK. Invited Speaker: Regulation of mammalian multidrug resistance-associated protein 2.

2006: Pathology Seminar Series, University of Cincinnati, Invited Speaker: Regulation of the synthesis and transport of bile acids during lactation. May 4, 2006.

2006: Invited Speaker, Wyeth, Cardiovascular and Metabolic Diseases, Cambridge, MA. Enterohepatic Bile Acid and Xenobiotic Transporters: Regulation in Pregnancy and Postpartum. 10/31/2006.

2007: Invited Speaker, Great Lakes Drug Metabolism Discussion Group, Ann Arbor, MI. Regulation of Organic Anion Transporters. May, 3-4, 2007.

Professional Activities – continued

19

Mary Vore

2008: Invited Speaker, and participant: Building a Stronger Science Culture within Pfizer PDM, La Jolla, CA April, 2008. Role of Mrp1 in Protection from Cardiac Injury

2008: Developed and Chair Symposia at Experimental Biology on Role of Transporters in Prevention and Exacerbation of Toxicity; April, 2008

2008: Invited Speaker, John Doull Symposium, University of Kansas, Department of Pharmacology and Toxicology; Regulation of Transporters and Bile Acid Metabolism in Lactation. 9/11/2008

2009: AAPS Workshop on Drug Transporters in ADME: From the Bench to the Bedside. 3/30-4/1,2009 Baltimore, MD. The role of Mrp2, MRP2 and MDR1 in Tissue Defense.

2009: International Symposium on Drug Transport and Metabolism, Oct 13 – 14, 2009, Buenos Aires, Argentina. MRP1 and tissue defense against doxorubicin cardiotoxicity.

2009: AAPS Annual Meeting – Invited Symposium Speaker, ABC Transporters in Tissue Defense: MRP1 and tissue defense against doxorubicin cardiotoxicity. Nov 12, 2009, Los Angeles, CA.

2010: Invited Speaker, Symposium on Pharmacogenomics, Nanjing, China, May 12 – 14, 2010. Single nucleotide polymorphisms (SNPs) in MRP1 (ABCC1) impact transport of products of oxidative stress.

2010: Invited Speaker, Microsomes and Drug Oxidations (MDO), Beijing, China, May 15-20, 2010. Regulation of transporters in the heart: MRP1 (ABCC1) and protection against cardiac injury.

2010: Invited Speaker, Institutional Development Award Meeting, Bethesda, MD June 17 – 19. Environmental Sciences and Public Health: The ABCs of Defense against Environmental Toxicants.

2011: Invited Speaker, International Society for the Study of Xenobiotics (ISSX); October 19, 2011. Atlanta, GA. Regulation of translation of human MRP2 (ABCC2).

2012: Invited Speaker, Chair of Symposia, International Society for the Study of Xenobiotics (ISSX); October 14-18, 2012.

D) Committee Service, NationalMember, Executive Council for the Drug Metabolism Division of ASPET, 1977-1980.Program Committee, Society of Toxicology, 1980-1983.Subcommittee on Public Information, ASPET 1980-83; Chairman, 1984.Society of Toxicology - American Society of Pharmacology and Experimental Therapeutics Liaison Program Committee for 1982 joint meeting.Membership Committee, ASPET, 1982-1985. Chair,1985.Board of Publications, Society of Toxicology, 1983-1987.ASPET Secretary-Treasurer Elect, 1986-1987. Secretary-Treasurer, 1987-1988; Past

Secretary-Treasurer, 1988-89. Awards Committee, Society of Toxicology, 1989-1991.Chairman, Drug Metabolism Division of ASPET - 1990-1992.Society of Toxicology, Mechanisms Section, Vice President Elect - 1995;

Vice President, 1996; President, 1997; Councilor, 1998.National Institute of Environmental Health Sciences External Review Working Group –

1995 -1997.American Association for the Study of Liver Disease – Abstract selection com: 1994FASEB, Excellence in Science Award Committee; 1995-1998; Chair, 1997, 1998ASPET, Bernard B. Brodie Award Committee: Chair, 1999-2001ASPET Member, Board of Publications Trustees, 2006 – 2011.ASPET, Program Committee: 1991 – 1994; 2007- 2009ASPET, Chair-elect; Division for Toxicology 2007 – 2008; Chair – 2008-2009; Past Chair – 2009-2010.ASPET, Secretary-treasurer elect 2010 – 2011ASPET, Secretary-treasurer 2011-2012ASPET, Past Secretary-treasurer 2012 - 2013

20

Mary Vore

Professional Activities – continued

E) Editorial Service and Manuscripts ReviewedAssociate Editor; 2011 – Present: Molecular PharmacologyEditorial Boards:

Drug Metabolism and Disposition: 1980 – 2011; Molecular Interventions: 2000 – 2010; American Journal of Physiology: Gastrointestinal and Liver: 2002 – 2009;Toxicology: 1978 -1983; Toxicology and Applied Pharmacology: 1979 – 1984;Trends in Pharmacological Sciences: 1988 - 1995. Environmental Health Perspectives: 1993-1996

Ad Hoc Reviewer for:Analytical Biochemistry; Archives of Biochemistry and Biophysics; Hepatology; Biochemical Pharmacology; Chemical and Biological Interactions; Journal of Pharmacology and Experimental Therapeutics; Gastroenterology;Toxicology and Applied Pharmacology; Molecular Pharmacology; Cancer Research; Journal of Biological Chemistry; Digestive Diseases and Sciences; Journal of Clinical Investigation; Proceedings, National Academy of Sciences;

F) Member of the Board of Scientific Counselors and Technical Reports Review Subcommittee of the National Toxicology Program 1981-83; 2002-2005. Member of the Nanoparticulate Working Group 2005

G) NIH Study Section ServiceAd Hoc; Pharmacology Study Section, NIH. February 1983; June 1990.Member, Pharmacology Study Section, NIH: 1983-1987.Chair, Special Toxicology Study Section, NIH: June 18, 1991.Special NIH Study Section, AIDS Clinical Trial Units: November 19, 1991.Chair, Hematology-2 Study Section; Special Emphasis Panel: April 1997Member, Alcohol/Toxicology 4 Study Section, NIH: 2000 – 2002; Chair 2002-2005 (Study section

changed to Xenobiotic and Nutrient Disposition and Action, XNDA, in 2004)Service on Special Review Groups for NIH – teleconference reviews: 2 in 2008; 2 in 2009; 1 in

2010; 2 in 2011; IAR – 1 in 2012; teleconference review: 1 in 2012H) Member of National Center for Toxicologic Research Scientific Peer Review Committee: 12/7-9/88. I) Reviewer, 1990 Howard Hughes Biomedical Institute Doctoral Fellowship in Biological

Sciences Program, Neurosciences and Physiology 1 Panel - 1990.J) Member, National Institutes of Health, National Advisory Environmental Health Sciences Council,

1991-1994. K) Applied Pharmacology Task Force, National Board of Medical Examiners, 1992-1993. L) Invited Participant National Institute of Environmental Health Sciences Directors Retreat; October

1994; December 1995.M) National Research Council, Committee on Toxicology, 1997-2000N) Member, Expert Panel Reports on Amphetamines and Methylphenidate; Center for the Evaluation of

Risks to Human Reproduction (CERHR); January 10-12, 2005.O) Member, External Advisory Committee: University of Washington, SCOR Grant, 2003 - 2006:

Mechanisms by which maternal and fetal drug disposition exposure is altered during pregnancy. PI J Unadkat

P) Member, External Advisory Committee, NIEHS Center for Comparative Toxicology, MDI Biological Laboratory, Salisbury Cove, ME. 2005 – 2009; PI – Dr. James L. Boyer

Q) External Advisory Committee, Superfund Basic Research Grant, “Health Impacts of Toxic Combustion By-Products”; Louisiana State University, LA. Dr. Barry Dellinger, PI; 2006 - 2012Meeting in Baton-Rouge, LA at LSU – Feb 23 – 24, 2010.

R) External Advisory Committee: NIEHS Training Grant in Toxicology. UCLA. Dr. Oliver Hankinson, PI. May 26-27, 2011.

21

Mary Vore

Professional Activities – continuedS) External Advisory Committee: NIEHS Training Grant (T32) in Toxicology, and Center for Integrative Toxicology (CIT), Drs. Norbert Kaminski and Robert Roth, Michigan State University, Lansing, MI. November 28-30, 2012.

FundingPast funding

1. The Effect of Endogenous Substrates on the Metabolism of Drugs and Other Xenobiotics by the Liver Mixed-Function Oxidase System in Pregnant Rats. Basil O'Connor Research Starter Grant National Foundation March of Dimes, PI, M Vore: 9/75-6/78.

2. Metabolic Activation of Carcinogenic Nitro Compounds, PI, M Vore: CA18435 1976-783. Lipid Requirement of the Lung Mono-oxygenase System, PI, M Vore: HL19605. 1976-784. Hepatic Drug Elimination in Pregnancy, PI; HD13250/GM55343: 9/1/79-12/05/20065. Calcium Regulation in Brain Aging and Alzheimer's Disease P01AG10836: PI, P. Landfield;

Project Leader, J. Carney; Co-Investigator, M Vore, 15% 8/20/92-7/31/96.6. Prolactin and Bile Secretory Function, PI, M Vore: DK 46923 5/1/94-6/30/2010.7. Short-term training in Environmental Toxicology, PI, M Vore: T35ES10951: 4/1/01 – 3/31/06.8. Roche Real-Time Polymerase Chain Reaction Workflow System -1S10 RR0235809. PI, M Vore: 2/1/08 – 1/31/099. Hepatic Drug Elimination in Pregnancy,

HD13250/GM55343/HD58299-025 PI, Mary Vore12/05/2006 – 11/30/2010; NCE – 11/30/2012 The goals of this grant are to define the mechanisms regulating translation of MRP2, an ATP-dependent efflux transporter, the effect of single nucleotide polymorphisms on substrate specificity and function, and the mechanisms of endocytic retrieval of MRP2 and the impact on function.

Current Funding: 10. The role of MRP1 in protection of cardiac injury: R01 CA139844

PI, Mary Vore 8/01/08 – 7/31/2013The goal of this grant is to characterize the importance of MRP1, an ATP-dependent efflux transporter, in protection against oxidative stress induced by doxorubicin, a cancer chemotherapeutic drug that induces cardiac injury.

11. Training Grant in Molecular Mechanisms of Toxicity, T32ES 07266 PI, Mary Vore7/1/95 - 6/30/2015

12. Summer Education Experience for Research R25 ES016248PI, Mary Vore 1/1/08 – 12/31/2013 The goal of this grant is to support the summer research in Toxicology of 6 undergraduate students from the University of Puerto Rico.

13. Clinical and Translational Science Award UL1RR0331737/2011 - 2016Kern, P: PIM Vore, Co-Director component for training mentors in clinical and translational sciences

14. Regulation of ABCG5 ABCG8 sterol transporter 2009-2013Graf, Greg: PI; M Vore Co-Inv

22

Mary Vore

15. MRP2 expression: Regulation by arsenic and effects on treatment outcomes in lung cancerPO2 415 1100000368 Kentucky Lung Cancer Research Program07/01/12 – 06/30/14The long term goals are to determine if 1) chronic exposure to arsenic increases expression of MRP2 in normal lung cells and 2) whether the MRP2 genotype and MRP2 expression in non-small cell lung cancers (NSCLC) impact NSCLC treatment outcomes.

Pending:16. Regulation of translation of human MRP2/ABCC2; competing renewal of HD58299

PI, Mary Vore07/01/2013 – 06/30/2018The goal of this grant is to define the mechanisms regulating translation of MRP2.

23